Category

Events
KD-CAAP is the first investigator driven trial funded by conect4children to have a site activated and to start the patients’ recruitment. KD-CAAP main objective is to  determine whether adding immediate corticosteroid treatment to standard of care (intravenous immunoglobulin (IVIG) and aspirin) will reduce coronary artery aneurysm (CAA) rates in Kawasaki Disease patients. Find more about...
Continue Reading
The 1st STAND4Kids Newsletter is now available. Read it. Download PDF
Continue Reading
STAND4KIds – Supporting Pediatric Trials in Portugal – it’s the national hub from the conect4children consortium (C4C – European Clinical Trials for Children), which is a large collaborative pediatric network that will facilitate the development of new drugs and other therapies for the entire pediatric population in Europe and is financed by the Innovative Medicines...
Continue Reading
On 25 th February took place the F2F meeting with Mark Turner (c4c Scientific Coordinator), Régis Hankard and Carla Owen, at AIDFM-CETERA office. STAND4Kids team was met by representatives from AIDFM (Vaz Carneiro, Vice President), FMUL (Fausto J. Pinto, Dean; and Catarina Pais Silva, European Project Manager) and SPP (André Graça, Treasurer). It was a...
Continue Reading
[ October 24th, 2018 ] In a joint organization between AIDFM-CETERA and SPP, the official launch of STAND4KIDS, the Portuguese national hub for the c4c project, was held on the morning of October 24th at Palácio Estoril Hotel.
Continue Reading
[ September 6th, 2018 ] The first National Hubs (NH) Meeting took place at the INSERM offices in Paris. There was a discussion about the role of NH in the different work packages and the perspectives from all NH represented were covered.
Continue Reading
[ May 23rd – 25th May, 2018 ] The c4c (conect4children) kick-off meeting took place in Berlin and it points out the beginning of a large collaborative pediatric network that will facilitate the development of new drugs and other therapies for the entire pediatric population in Europe.
Continue Reading
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA